Pooled 3-year overall survival data from phase II and phase III trials of nivolumab (NIVO) combined with ipilimumab (IPI) in advanced melanoma Meeting Abstract
| Authors: | Postow, M.; Larkin, J.; Wolchok, J.; Chiarion-Sileni, V.; Hodi, F. S.; Rutkowsk, P.; Grob, J. J.; Grossmann, K.; Schadendorf, D.; Chesney, J.; Smylie, M.; Hill, A.; Robert, C.; Pavlick, A. C.; Haanen, J.; McArthur, G. A.; McDermott, D.; Demelo, S.; Bhore, R.; Gonzalez, R. |
| Abstract Title: | Pooled 3-year overall survival data from phase II and phase III trials of nivolumab (NIVO) combined with ipilimumab (IPI) in advanced melanoma |
| Meeting Title: | 32nd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2017) |
| Journal Title: | Journal for ImmunoTherapy of Cancer |
| Volume: | 5 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2017 Nov 8-12 |
| Meeting Location: | National Harbor, MD |
| ISSN: | 2051-1426 |
| Publisher: | Biomed Central Ltd |
| Date Published: | 2017-11-07 |
| Start Page: | 86 |
| Language: | English |
| DOI: | 10.1186/s40425-017-0289-3 |
| PROVIDER: | manual |
| Notes: | Meeting Abstract: O21 |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work